CAR-T Therapy for CLL: Real-World Data Shows Promise
For patients battling chronic lymphocytic leukemia (CLL), new hope is emerging from the growing body of evidence surrounding CAR-T therapy, specifically lisocabtagene maraleucel (liso-cel). While clinical trials have demonstrated efficacy, recent real-world data suggests that liso-cel may be even more effective in a broader patient population.
Beyond the Clinical Trial: Why Real-World Data Matters
Historically, medical advancements are first tested in rigorous clinical trials. These trials, while essential, often involve carefully selected patients who meet strict criteria. This can limit the generalizability of the findings. Real-world data, gathered from everyday clinical practice, provides a more comprehensive picture of how a treatment performs in a diverse group of individuals.
Researchers, including Dr. Mazyar Shadman from Fred Hutch Cancer Center, are now focusing on this real-world evidence. Their findings, presented at the American Society for Hematology (ASH) Annual Meeting in 2025, indicate that liso-cel delivers response rates comparable to, and potentially exceeding, those observed in clinical trials.
Impressive Response Rates in Real-World Settings
A recent study analyzing data from 30 patients with CLL treated with liso-cel in the United States revealed an overall response rate of 83%. Notably, 60% of patients achieved a complete response, meaning no detectable signs of cancer. This is particularly encouraging given that the patients in this study had received a median of six prior lines of therapy, and 80% had previously undergone chemotherapy. All patients had previously been treated with both a BTK inhibitor and a BCL2 inhibitor.
These results align with broader observations. Data indicates that liso-cel drives high responses in relapsed or refractory CLL, with an 85% overall response rate and a 44% complete response rate. The safety profile similarly appears manageable, reinforcing its potential as a valuable treatment option.
Durability of Response: Long-Term Outcomes
The benefits of liso-cel aren’t just immediate. Studies have shown persistence of the liso-cel transgene detected up to 48 months after infusion in some patients. This suggests the potential for durable responses, offering patients extended periods of remission. An updated follow-up study demonstrated an extended median overall survival of 43.2 months in patients with relapsed or refractory CLL/SLL.
Did you know? Liso-cel is currently the only CAR-T therapy approved by the FDA for treating CLL/SLL.
The Role of Prior Therapies and Genetic Markers
The study highlighted that 67% of patients included had deletion 17p or a TP53 mutation, genetic markers often associated with more aggressive disease and poorer prognosis. The fact that liso-cel demonstrated efficacy in this subgroup is particularly significant. 60% of patients had received pirtobrutinib as their last line of treatment before liso-cel, indicating the therapy can be effective even after resistance to other targeted treatments.
Future Trends and the Expanding Landscape of CAR-T Therapy
The success of liso-cel in both clinical trials and real-world settings is paving the way for further advancements in CAR-T therapy for CLL. Researchers are exploring ways to optimize the therapy, potentially reducing side effects and improving response rates. This includes investigating different CAR designs, conditioning regimens, and methods for enhancing T-cell persistence.
As more data emerges, we can expect to see CAR-T therapy integrated earlier into the treatment paradigm for CLL, potentially offering a curative option for a larger number of patients. The approval of liso-cel in the United States in March 2024 marked a significant milestone, and ongoing research will continue to refine its use and expand its reach.
FAQ
Q: What is CAR-T therapy?
A: CAR-T therapy reprograms your body’s own immune cells to recognize and destroy cancer cells.
Q: Is liso-cel right for everyone with CLL?
A: Liso-cel is typically considered for patients with relapsed or refractory CLL who have exhausted other treatment options.
Q: What are the potential side effects of liso-cel?
A: The safety profile of liso-cel is manageable, but like all therapies, it can have side effects. These are typically monitored and managed by a healthcare team.
Q: Where can I learn more about CLL and CAR-T therapy?
A: The CLL Society is a valuable resource for patients and caregivers.
Pro Tip: Discuss all treatment options with your oncologist to determine the best course of action for your individual situation.
Stay informed about the latest advancements in CLL treatment. Share this article with others who may benefit from this information. Explore more articles on our website or subscribe to our newsletter for regular updates.
